Argenx Se (ARGX) has released an update.
Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval from China’s National Medical Products Administration for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), marking it as the first approved therapy for this condition in China. This approval is seen as a significant advancement for patients who have long been in need of effective treatment options. The decision is based on successful trial results showing a substantial reduction in CIDP relapse risk.
For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.
